UPDATE: Janney Montgomery Scott Maintains Sarepta Therapeutics (SRPT) to Buy

(Updated - January 3, 2017 9:25 AM EST)

(Correction: Stock was not upgraded)

Janney Montgomery Scott maintained a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT) with a price target of $65.00.

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $27.43 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Deutsche Bank Upgrades MSCI Inc. (MSCI) to Buy, 'Compelling entry point for long-term investors'
• Loop Capital Upgrades Sea Ltd. (SE) to Buy, 'shift to sustained profitable growth is finally underway'
• Bernstein SocGen Group Upgrades CapCom Co Ltd. (9697:JP) (CCOEY) to Outperform